Nakanishi H, Abe A, Inada K, Tsukamoto T, Yasui K, Tatematsu M
Laboratory of Pathology, Aichi Cancer Center Research Institute, Kanokoden, Chikusa-ku, Nagoya 464, Japan.
J Cancer Res Clin Oncol. 1999 Dec;125(12):660-8. doi: 10.1007/s004320050331.
Antimetastatic effects of 5-FU and its derivative, 1-hexylcarbamoyl-5-fluorouracil (HCFU) on human gastric cancer micrometastasis and their mode of action were evaluated, using a spontaneous lung metastasis model (HY-1) in nude mice. Metastases were first detected in the lung from 4 weeks after subcutaneous transplantation, growing intravascularly and forming micrometastases at 100% incidence by 6 weeks after implantation. Lung metastasis in mice bearing subcutaneous tumors was significantly inhibited by HCFU at doses of 100-150 mg kg(-1) day(-1) without severe toxic side-effects, when orally administered three times per week either from week 4 or week 6 to 9 weeks after implantation. Spontaneous lung metastasis was also inhibited by the administration of 5-FU, but to lesser extent than with HCFU at equimolar low doses. Apoptosis within primary tumors and lung metastatic foci, as detected by the terminal-deoxynucleotidyltransferase-mediated dUTP nick-end labeling method, was found to be significantly enhanced by HCFU as well as 5-FU administration at doses of more than 100 mg kg(-1) day(-1) and 50 mg kg(-1) day(-1) respectively. However, proliferating activity of the metastatic foci, as evaluated by MIB-1 immunostaining, was not significantly suppressed by HCFU or 5-FU treatment. Furthermore, polymerase chain reaction analysis using human specific primers for the beta-globin gene, which proved to be capable of detecting 10 tumor cells/ml mouse blood, revealed that circulating tumor cells in the peripheral blood of mice bearing primary tumors were reduced by HCFU or 5-FU administration. These results indicate that circulating tumor cells in blood and micrometastases in the lung are sensitive to these chemotherapeutic agents, and suggest that the anti-metastatic effect of these agents is mediated, at least in part, by enhanced apoptosis rather than by inhibition of cell proliferation.
利用裸鼠自发性肺转移模型(HY-1)评估了5-氟尿嘧啶(5-FU)及其衍生物1-己基氨基甲酰基-5-氟尿嘧啶(HCFU)对人胃癌微转移的抗转移作用及其作用方式。皮下移植后4周开始在肺中首次检测到转移,肿瘤在血管内生长,到植入后6周时100%发生微转移。从植入后第4周或第6周开始至第9周,每周口服给药3次,剂量为100 - 150 mg·kg⁻¹·d⁻¹的HCFU可显著抑制皮下荷瘤小鼠的肺转移,且无严重毒性副作用。给予5-FU也可抑制自发性肺转移,但在等摩尔低剂量时其抑制程度小于HCFU。采用末端脱氧核苷酸转移酶介导的dUTP缺口末端标记法检测发现,分别给予剂量超过100 mg·kg⁻¹·d⁻¹的HCFU和50 mg·kg⁻¹·d⁻¹的5-FU后,原发性肿瘤和肺转移灶内的凋亡显著增强。然而,通过MIB-1免疫染色评估,转移灶的增殖活性并未被HCFU或5-FU治疗显著抑制。此外,使用人β-珠蛋白基因特异性引物的聚合酶链反应分析表明,该方法能够检测到每毫升小鼠血液中10个肿瘤细胞,结果显示给予HCFU或5-FU后,荷原发性肿瘤小鼠外周血中的循环肿瘤细胞减少。这些结果表明,血液中的循环肿瘤细胞和肺中的微转移对这些化疗药物敏感,提示这些药物的抗转移作用至少部分是通过增强凋亡而非抑制细胞增殖来介导的。